Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous and intravenous use. It is employed to prevent and treat thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, and to reduce clot formation during haemodialysis.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Ledraxen, a low molecular weight heparin, acts on the coagulation cascade to reduce clot formation in several clinical settings. - Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical patients at risk of DVT. - Acute DVT and pulmonary embolism (PE) treatment: facilitates clot resolution and reduces recurrence. - Haemodialysis clot prophylaxis: minimizes clotting in the extracorporeal circuit during dialysis sessions.

Common Side Effects: - Injection site erythema or bruising. - Mild gastrointestinal bleeding. - Nausea or vomiting. - Elevated liver enzymes. - Transient headache. - Localized pain at the injection site.

Serious or Rare Side Effects: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as urticaria or anaphylaxis. - Spinal or epidural hematoma following neuraxial procedures. - Severe hypotension. - Disseminated intravascular coagulation (DIC).

Ledraxen should be used with caution in patients with renal impairment, active bleeding, or a history of heparin‑induced thrombocytopenia. - Renal impairment: adjust dose or monitor anti‑Xa levels. - Active bleeding: avoid use unless benefits outweigh risks. - Concomitant anticoagulants: increase bleeding risk; monitor coagulation parameters. - Platelet monitoring: check counts regularly to detect HIT. - Obesity or extreme body weight: consider dose adjustments. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Enoxaparin may interact with several drug classes, influencing bleeding risk or anticoagulant effect.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct thrombin inhibitors). - Combination with antiplatelet agents (e.g., aspirin, clopidogrel) that heighten bleeding. - Use with fibrinolytic therapy (e.g., alteplase) may cause severe hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can increase gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) that may impair platelet function. - ACE inhibitors or angiotensin receptor blockers that can potentiate hypotensive effects when combined with anticoagulation.